Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
173.5(c) 170(c) 170.55(c) 172.1(c) 166.1(c) Last
234 396 259 321 395 838 235 733 412 334 Volume
+0.38% -2.02% +0.32% +0.91% -3.49% Change
More quotes
Estimated financial data (e)
Sales 2021 16 400 M 2 497 M 2 497 M
Net income 2021 1 322 M 201 M 201 M
Net Debt 2021 2 427 M 370 M 370 M
P/E ratio 2021 24,9x
Yield 2021 1,62%
Sales 2022 17 655 M 2 688 M 2 688 M
Net income 2022 1 981 M 302 M 302 M
Net cash position 2022 177 M 26,9 M 26,9 M
P/E ratio 2022 16,9x
Yield 2022 2,24%
Capitalization 33 004 M 5 021 M 5 026 M
EV / Sales 2021 2,16x
EV / Sales 2022 1,86x
Nbr of Employees 5 588
Free-Float 30,7%
More Financials
Company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression... 
Sector
Pharmaceuticals
Calendar
02/09Earnings Release
More about the company
Ratings of H. Lundbeck A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about H. LUNDBECK A/S
11/25H LUNDBECK A/S : From Drughunters winner to neuropsychologist
PU
11/15Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migra..
AQ
11/15Lundbeck Launches Mid-Stage Study For Migraine Prevention Treatment
MT
11/15Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migr..
AQ
11/15Lundbeck Announces Start of a Phase II Clinical Study to Assess Lu AG09222 for Migraine..
CI
11/12Lundbeck's Migraine Treatment Lands Positive Opinion From European Medicines Agency
MT
11/12Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migra..
AQ
11/12H. Lundbeck A/S's Vyepti Recommends for Approval in the EU by CHMP for the Preventive T..
CI
11/10Lundbeck Affirms Lower Revenue Forecast For FY21
MT
11/10Lundbeck continues solid operational performance with strong growth from strategic bran..
AQ
11/10H. Lundbeck A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
11/08Lundbeck to Kick Off Mid-Stage Study for Multiple System Atrophy Treatment
MT
11/08Lundbeck launches a phase II study for potential new treatment of multiple system atrop..
AQ
11/08H. Lundbeck A/S Launches Phase II Study for Potential New Treatment of Multiple System ..
CI
11/08H. Lundbeck A/S Launches A Phase II Study for Potential New Treatment of Multiple Syste..
CI
More news
News in other languages on H. LUNDBECK A/S
11/24OPINIONES DE LOS ANALISTAS DEL DÍA : Apple, Clariant, Deliveroo, Siemens, Juste Eat, NEL, ..
11/24Pluie de données avant la dinde
11/24AVIS D'ANALYSTES DU JOUR : OVH, McPhy, Bic, Ipsen, NEL, Vifor, UCB, SMA Solar...
11/15Lundbeck lance une étude de mi-parcours pour un traitement de prévention de la migraine
11/12Le traitement de la migraine de Lundbeck reçoit un avis positif de l'Agence européenne ..
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 166,10 DKK
Average target price 224,81 DKK
Spread / Average Target 35,3%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Søren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-20.45%5 021
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049